Novartis sales and earnings
This article was originally published in The Tan Sheet
Executive SummaryNovartis' health care portfolio helps it achieve a record $39.8 billion in net sales in 2007, an 8 perent increase, the firm announced Jan. 17. Novartis attributes its success in part to its OTC and animal health performance - despite a weak cough and cold season in the U.S. - because of renewed focus on strategic brands, new product launches and expansions. Novartis' operating income also went up 15 percent to $85 million for consumer health continuing operations thanks to a better product mix and a reduction in operation costs, the Swiss firm says in a statement. Fourth quarter net sales grew 6 percent to $9.93 billion Consumer Health grew 14 percent to $1.41 billion, helping to offsest "negative developments in Pharmaceuticals in the U.S. and a weaker quarter in Vaccines and Diagnostics" that contributed to net income of $931 million, a 42 percent decrease from the prior-year quarter...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.